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Summary 
This project was to provide analytical determination for the concentrations of residual fluoroquinolone antibiotics after ozonation 
treatment using the published method by the PI (Renew and Huang, 2004, J. Chromatogr. A., 1042, 113-121). The overall objective 
of the project was to assess whether micro-bubble ozonation was an effective mean t o remove emerging contaminants such as 
fluoroquinolone antibiotics in water. The analyses were conducted for five different sets of batch tests. The analytical results of these 
samples were reported previously to the sponsor and are summarized in^his report. In general, high percentage removal was seen by 
this ozonation approach. 
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A. Analytical Results of 07/14/06: 
Sample descriptions: 
Sample# Sample description i - . - - n . 
Sample 1 Dechlorinated tap, 988 mL • ,,; 
Sample 2 1:10 waste sample with no FQ's, 1.0 L 
Add 5.844gNaCl to 1L
 :,A r ^ v . 
Add phosphoric acid to ~2.5pH - >i-ifr 
Filter through 0.7um glass fiber filter 
Sample 3 Dechlorinated tap water with FQ's spike, low concentration, send 1.0 L 
Add 11.688gNaClto2L 
Add phosphoric acid to ~2.5pH 
Add 20uL of Levo. Stock (lOOOmg/L) 
Add 80 uL of Cipro. Stock (25 Omg/L) 
Sample 4 Waste sample high concentration, 40mL amber vial (Chemical addition and FQ addition based on 1 L) 
Add 5.844gNaClto 1L 
Add phosphoric acid to ~2.5pH 
Add 1 OmL of Levo. Stock (1 OOOmg/L) 
Add 40mL of Cipro. Stock (250mg/L) 
Filter through 0.7um glass fiber filter ! ; 
- Samples 1-3 were concentrated by solid phase extraction (SPE) prior to analysese. 
- Sample 4 was analyzed directly without SPE or any pretreatment. 
SPE: Each sample (988-1000 mL) was extracted through a 500 mg anion-exchange cartridge stacked on top of a 500 mg 
hydrophilic-lipophilic balance cartridge. Each sample was amended with 10 \ i g / L lomefloxacin prior to extraction for evaluation of 
extraction recoveries. After the extraction, 1 mg/L norfloxacin was spiked into the concentrated samples as an internal standard to 
account for signal suppression effects in different water matrices. 
R e s u l t s 
I. Samples concentrated by SPE: 
Norfloxacin Ciprofloxacin Levofloxacin Lomefloxacin 
Sample # A r e a i s , d A r e a I A r e a / A r e a ^ d I Conc.(mg/L) A r e a I A r e a / A r e a t a S Conc.(mg/L) A r e a \ A r e a / A r e a ^ d Conc.(mg/L) 
Sample 1 5167447.5 ND ND ND , ND ND ND 69189216 13.39 8.10 
Sample 2 2956971 ND ND ND ND I ND ND 9378519 3.17 2.10 
Sample 3 6096668.5 6748697 ! 1.11 | 1.18. 44758832 j 7.34 j 4.56 52934660 ! 8.68 5.33 
ND = not detectable. 
Recovery calculation 





Concentration corrected by recovery 
Ciprofloxacin (ug/L) Levofloxacin (ug/L) 
Sample 1 988 8.00 80.04 ND ND 
Sample 2 1000 2.10 20.95 ND ND 
Sample 3 1000 5.33 53.34 2.22 8.55 
II. Samples without SPE: 
Sample# Ciprofloxacin Ofloxacin 
Area Conc.(mg/L) Area Conc.(mg/L) 
Sample 4 29540820 | 2.78 54620428 | 3.49 
Summary : 
1. Ciprofloxacin and levofloxacin were not detected in the unspiked dechlorinated tap water or wastewater. 
2. Ciprofloxacin and levofloxacin were determined to be 2.78 mg/L and 3.49 mg/L in the spiked dechlorinated tap water. These 
concentrations were lower than the indicated - 1 0 mg/L spiking concentration. Degradation of the FQs is unlikely the cause. This 
may be due to errors in the stocks. 
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3. The low recovery of Sample 2 is likely due to human errors in the SPE procedures (i.e„ during the the blow-down step). The 
recovery is expected to improve the next time. 
4. Overall, accurate analyses of the FQs for study can be conducted in the selected matrices. 
A p p e n d i x : 
C a l i b r a t i o n c u r v e : 
Standards of fluoroquinolones 
Peak Area 
Norfloxacin Ciprofloxacin Ofloxacin Lomefloxacin 
mg/L MW320 MW332 MW362 MW352 
S1 0.5 7348863 7532340 8927217 10020725 
S2 2 13599119 14087239 20648978 21137282 
S3 5 62212280 56669268 88743072 84674992 
S4 10 122698864 115556520 161615568 158451744 
S5 15 174035424 171717120 232969536 246389712 
Note: Ofloxacin was used as the standard for levofloxacin in this around of analyses. 
Calibration curve of norfloxacin: ZE*OS 
Z B 0 8 







Z & 0 7 
O.&OO 
y = 11959017.444x - 1754703.386 
F? = 0.993 
2 4 6 * 8 t ) 12 
Nbrfloxacin cone. (mg/L) 
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Integrated area of 1 mg/L norfloxacin = 9763424 
Norfloxacin were added in all of the samples and standards as an internal standard. The peak area of each FQ (except for norfloxacin) 
was normalized by the peak area of 1 mg/L norfloxacin (i.e., Area/Areais t d). Calibration curves were generated by plotting Area/Areai s t d 
ratios versus the concentration of each FQ. 
Area/ Areai s t d 
Ciprofloxacin Ofloxacin Lemofloxacin 
mg/L MW332 MW362 MW352 
S1 0.5 0.77 0.91 1.03 
S2 2 1.44 2.11 2.16 
S3 5 5.80 9.09 8.67 
S4 10 11.84 16.55 16.23 






y = 1.1965x-0.2885 
= 0.9966 
0 5 10 15 
Ciprofloxacin cone. (mg/L) 
y = 1.6232x-0.0443 
F?= 0.9932. 
5 10 
Ofloxacin c o n e (mg/L) 
15 
y = 1.6951x-0.3523 
=0.9963 
5 10 15 
Lemofloxacin cone. (mg/L) 
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B. Analytical Results of 08/10/06: 
Group I 
Received 
Date Description pH Precipitation 
Ciprofloxacin Levofloxacin 
Integrated Area Cone. (mg/L) Integrated Area Cone. (mg/L) 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Initial Rep1 - a 2.41 84865392 4.69 153210272 10.13 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Initial Rep1 - b 2.43 84520536 4.66 112742984 6.08 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Initial Rep2 - a 2.29 100381488 5.93 153383696 10.15 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Initial Rep2 - b 2.34 83172208 4.56 145149968 9.33 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Final Rep1 - a 2.84 Yes 85976864 4.78 149775840 9.79 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Final Rep1 - b 2.8 Yes 87958008 4.94 118822608 6.69 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Final Rep2 - a 2.81 Yes 89059896 5.03 109992968 5.81 
8.3.06 1 20 Hydoz -10 mg/L FQ 7.31.06 Final Rep2 - b 2.8 Yes 78920984 4.22 103408720 5.15 
8.3.06 1 10 Hydoz -10 mg/L FQ 7.31.06 Initial Rep1 - a 2.34 106275880 6.40 126509640 7.46 
8.3.06 1 10 Hydoz -10 mg/L FQ 7.31.06 Initial Rep1 - b 2.34 100570184 5.95 123606136 7.17 
8.3.06 1 10 Hydoz -10 mg/L FQ 7.31.06 Initial Rep2 - a 2.33 109030632 6.62 155565776 10.37 
8.3.06 1 10 Hydoz -10 mg/L FQ 7.31.06 Initial Rep2 - b 2.32 102007640 6.06 118075672 6.62 
8.3.06 1 10 Hydoz -10 mg/L FQ 7.31.06 Final Rep1 - a 2.31 Yes 93755088 5.40 133847912 8.19 
8.3.06 1 10 Hydoz -10 mg/L FQ 7.31.06 Final Rep1 - b 2,58 Yes 77240616 4.08 97381240 4.55 
8.3.06 1 10 Hydoz-10 mg/L FQ 7.31.06 Final Rep2 - a 2.91 Yes 93164224 5.36 105665128 5.38 
8.3.06 1 10 Hydoz -10 mg/L FQ 7.31.06 Final Rep2 - b 2.9 Yes 85817584 4.77 90735200 3.88 
8.3.06 1 5 Hydoz -10 mg/L FQ 8.1.06 Initial Rep1 - a 2.26 85112000 4.71 98188032 4.63 
8.3.06 1 5 Hydoz -10 mg/L FQ 8.1.06 Initial Rep1 - b 2.29 84585024 4.67 96329064 4.44 
8.3.06 1 5 Hydoz -10 mg/L FQ 8.1.06 Initial Rep2 - a 2.25 95653472 5.55 99163200 4.73 
8.3.06 1 5 Hydoz-10 mg/L FQ 8.1.06 Initial Rep2 - b 2.26 82698736 4.52 92514176 4.06 
8.3.06 1 5 Hydoz -10 mg/L FQ 8.1.06 Final Rep1 - a 2.03 Yes 193128560 13.35 47316196 0.87 
8.3.06 1 5 Hydoz -10 mg/L FQ 8.1.06 Final Rep1 - b 1.99 Yes 175536160 11.94 40872156 0.79 
8.3.06 1 5 Hydoz -10 mg/L FQ 8.1.06 Final Rep2 - a 2.12 Yes 64189604 3.04 67393872 1.55 
8.3.06 1 5 Hydoz -10 mg/L FQ 8.1.06 Final Rep2 - b 2.16 Yes 64049896 3.03 65482848 1.36 
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8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Initial Rep1 - a .2.3 93362632 5.37 98097496 4.62 
8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Initial Rep1 - b 2.3 91602296 5.23 94864656 4.30 
8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Initial Rep2 - a 2.25 Yes 41085124 1.19 49444064 0.89 
8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Initial Rep2 - b 2.27 75927088 3.98 86183992 3.43 
8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Final Rep2 - a 2.29 86186032 4.80 87028848 3.51 
8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Final Rep2 - b 2.27 Yes 48361296 1.77 50910632 0.91 
8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Final Rep2 - a 2.09 Yes 29021948 0.22 36599096 0.73 
8.3.06 1 3 Hydoz -10 mg/L FQ 8.1.06 Final Rep2 - b 2.12 Yes 39292308 1.05 40720036 0.79 
Group I I 
Received 
Date Description pH Precipitation 
Ciprofloxacin Levofloxacin 
Integrated Area Cone. (mg/L) Integrated Area Cone. (mg/L) 
8.3.06 Dechlorinated Tap FQ spiked 7.31.06 - a 2.34 95973632 5.58 153798992 10.19 
8.3.06 Dechlorinated Tap FQ spiked 7.31.06 - b 2.31 91350264 5.21 113752824 6.19 
8.3.06 
Dechlorinated Tap 8.1.06-10 mg/L FQ Pre Test Sample 8.1.06 2 
- a 2.2 75907152 3.97 95029256 4.31 
8.3.06 
Dechlorinated Tap 8.1.06 -10 mg/L FQ Pre Test Sample 8.1.06 2 
-b 2.22 89611824 5.07 100180176 4.83 
8.5.06 
Dechlorinated Tap FQ spike -10 mg/L FQ Pre Test Sample 8.2.06 -
a 7.41 68785176 3.40 79709984 2.78 
8.5.06 
Dechlorinated Tap FQ spike -10 mg/L FQ Pre Test Sample 8,2.06 -
b 2.7 Yes 51408536 2.01 62494840 1.06 
Group I I I 
Received 
Date Description pH Precipitation 
Ciprofloxacin Levofloxacin 
Integrated Area Cone. (mg/L) Integrated Area Cone. (mg/L) 
8.4.06 Bubble Ozone Test Initial Rep1 8.2.06 6.5cfh ozone - a 2.22 61375376 2.81 78696456 2.68 
8.4.06 Bubble Ozone Test Initial Rep1 8.2.06 6.5cfh ozone - b 2.26 71045280 3.59 87021192 3.51 
8.4.06 Bubble Ozone Test Initial Rep2 8.2.06 6.5cfh ozone - a 2.2 60020184 2.70 77530600 2.56 
8.4.06 Bubble Ozone Test Initial Rep2 8.2.06 6.5cfh ozone - b 2.24 62310588 2.89 80140784 2.82 
8.5.06 Bubble Ozone Test Final Rep1 8.2.06 6.5cfh ozone - a 2.46 Yes 45928844 1.58 57169260 0.99 
8.5.06 Bubble Ozone Test Final Rep1 8.2.06 6.5cfh ozone - b 2.46 43767960 1.40 55756028 0.97 
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8.5.06 Bubble Ozone Test Final Rep2 8.2.06 6.5cfh ozone - a 2.45 Yes 51355556 2.01 61495192 0.96 
8.5.06 Bubble Ozone Test Final Rep2 8.2.06 6.5cfh ozone - b 2.44 Yes 51491596 2.02 62363720 1.05 
8.4.06 Bubble Ozone Test Initial Rep1 8.2.06 3.0cfh ozone - a 2.19 57885828 2.53 71303544 1.94 
8.4.06 Bubble Ozone Test Initial Rep1 8.2.06 3.0cfh ozone - b 2!24 68132040 3.35 70541416 1.86 
8.4.06 Bubble Ozone Test Initial Rep2 8.2.06 3.0cfh ozone - a 2.26 75342608 3.93 82663840 3.08 
8.4.06 Bubble Ozone Test Initial Rep2 8.2.06 3.0cfh ozone - b 2.26 68236688 3.36 72576304 2.07 
8.5.06 Bubble Ozone Test Final Rep1 8.2.06 3.0cfh ozone - a 2.89 Yes 49695004 1.88 64441900 1.25 
8.5.06 Bubble Ozone Test Final Rep1 8.2.06 3.0cfh ozone - b 2.9 Yes 50402432 1.93 62047584 1.01 
8.5.06 Bubble Ozone Test Final Rep2 8.2.06 3.0cfh ozone - a 7.35 63288984 2.97 76705944 2.48 
8.5.06 Bubble Ozone Test Final Rep2 8.2.06 3.0cfh ozone - b 2.67 Yes 53595672 2.19 63250476 1.14 
Group IV 
Received 
Date Description ,pH Precipitation 
Ciprofloxacin Levofloxacin 
Integrated Area Cone. (mg/L) Integrated Area Cone. (mg/L) 
8.4.06 20 mg/L Chlorine Test 8.2.06 Initial Rep1 - a - ~ 2.3 77264864 4.08 85330640 3.34 
8.4.06 20 mg/L Chlorine Test 8.2.06 Initial Rep1 - b 2.31 78078832 4.15 85752368 3.39 
8.4.06 20 mg/L Chlorine Test 8.2.06 Initial Rep2 - a 2.21 76969960 4.06 82566312 3.07 
8.4.06 20 mg/L Chlorine Test 8.2.06 Initial Rep2 - b 2.28 71350690 3.61 78408048 2.65 
8.5.06 20 mg/L Chlorine Test 8.2.06 Final Rep1 - a 3.1 Yes 35209896 0.72 66040988 1.41 
8.5.06 20 mg/L Chlorine Test 8.2.06 Final Rep1 - b 3.09 Yes 34245888 0.64 64378484 1.25 
8.5.06 20 mg/L Chlorine Test 8.2.06 Final Rep2 - a 3.06 Yes 33014624 0.54 64009960 1.21 
8.5.06 20 mg/L Chlorine Test 8.2.06 Final Rep2 - b 3.07 Yes 28625118 0.19 60676360 1.03 
8.4.06 10 mg/L Chlorine Test 8.2.06 Initial Rep1 - a 2.29 78430912 4.18 83564104 3.17 
8.4.06 10 mg/L Chlorine Test 8.2.06 Initial Rep1 - b 2.33 69402808 3.45 78487944 2.66 
8.4.06 10 mg/L Chlorine Test 8.2.06 Initial Rep2.-a 2.27 69859216 3.49 75977144 2.41 
8.4.06 10 mg/L Chlorine Test 8.2.06 Initial Rep2 - b 2.-3 65968748 3.18 73007872 2.11 
8.5.06 10 mg/L Chlorine Test 8.2.06 Final Rep1-a 2.59 Yes 38275656 0.96 67349640 1.55 
8.5.06 10 mg/L Chlorine Test 8.2.06 Final Rep1 - b 2.6 Yes 37957824 0.94 63639328 1.17 
8.5.06 10 mg/L Chlorine Test 8.2.06 Final Rep2 - a 3.16 Yes 41090572 1.19 58006248 1.00 









S1 0.25 2407772.5 5811350.7; 
S2 0.5 10512725 14507997 
S3 0.75 22354160 27656472 
S4 32688936 62590152 
S5 52499508 71005392 
S6 97477864 108285344 
S7 7.5 121786712 128267360 










y = 12114556.762X + 27476604.516 
0.977 
2 4 6 8 10 
Ciprofloxacin cone. (mg/L) 
y = 10107591.843X+ 53002150.399 
r f = 0.995 
2 4 6 8 10 
Levofloxacin cone (mg/L) 
9 
C. Analytical Results of 09/02/06: 
Sample descriptions: 
Sample # Sample description Date pH Precipitation 
1 Pre-test Sample FQ addition 8/22/2006 2.32 No 
2 1:10 Initial Rep 1 8/22/2006 2.39 No 
3 1:10 Initial Rep2 . 8/22/2006 2.25 No 
4 1:10 Final Repl 8/22/2006 2.46 No 
5 1:10 Final Rep2 8/22/2006 2.46 No 
6 1:20 Initial Repl 8/22/2006 2.34 No 
7 1:20 Initial Rep2 8/22/2006 2.24 No 
8 1:20 Final Repl 8/22/2006 1.9 No 
9 1:20 Final Rep2 8/22/2006 2.5 No 
10 Pre-test Sample FQ spiked 8/23/2006 2.38 No 
11 1:3 HYDOZ Initial Repl 8/23/2006 2.32 No 
12 1:3 HYDOZ Initial Rep2 8/23/2006 2.23 No 
13 1:3 HYDOZ Final Repl 8/23/2006 2.93 Yes 
14 1:3 HYDOZ Final Rep2 8/23/2006 2.42 Yes 
15 1:5 HYDOZ Initial Repl 8/23/2006 3.27 No 
16 1:5 HYDOZ Initial Rep2 8/23/2006 2.34 No 
17 1:5 HYDOZ Final Repl 8/23/2006 3.04 Yes 
18 1:5 HYDOZ Final Rep2 8/23/2006 2.47 Yes 
19 Bubble 0 3 3.0 cm Initial Repl 8/26/2006 2.7 No 
20 Bubble 0 3 3.0 cm Initial Rep2 8/26/2006 2.69 No 
21 Bubble 0 3 3.0 cm Final Repl 8/26/2006 2.71 No 
22 Bubble 0 3 3.0 cm Final Rep2 8/26/2006 2.72 No 
23 Bubble 0 3 6.5 cm Initial Repl 8/26/2006 2.57 No 
24 Bubble 0 3 6.5 cfh Initial Rep2 8/26/2006 2.85 No 
25 Bubble 0 3 6.5 cfh Final Repl 8/26/2006 2.81 No 
26 Bubble 0 3 6.5 cfh Final Rep2 8/26/2006 2.98 No 
27 Pre-test Sample FQ spiked 8/28/2006 2.44 No 
28 10 mg/L CI Dosage Initial Repl 8/28/2006 3.57 Yes 
29 10 mg/L CI Dosage Initial Rep2 8/28/2006 2.5 No 
30 10 mg/L CI Dosage Final Repl 8/28/2006 3.97 Yes 
31 10 mg/L CI Dosage Final Rep2 8/28/2006 2.93 Yes 
32 20 mg/L CI Dosage Initial Repl 8/28/2006 3.38 No 
33 20 mg/L CI Dosage Initial Rep2 8/28/2006 2.51 No 
34 20 mg/L CI Dosage Final Repl 8/28/2006 4.01 Yes 
35 20 mg/L CI Dosage Final Rep2 8/28/2006 3.54 No 
Samples with precipitation were filtered by 0.7 um glass filters before solid phase extraction (SPE). All samples (972-1000 mL) were 
extracted through a 500 mg anion-exchange cartridge stacked on top of a 500 mg hydrophilic-lipophilic balance cartridge. Sample 1 -
26 were amended with 10 ug/L lomefloxacin and Sample 27 - 35 were amended with 20 \igfL lomefloxacin prior to extraction for 
evaluation of extraction recoveries. After the extraction, 1 mg/L norfloxacin was spiked into the concentrated samples as an internal 
standard to account for signal suppression effects in different water matrices. 
Results: 
Norfloxacin Ciprofloxacin Levofloxacin Lomefloxacin 
Sample # Areai s M Area Area/ Areata Conc.(mg/L) Area Area/ Areata Cone.(mg/L) Area Area/ Areaistd Conc.(mg/L) 
1 2 8 0 5 0 7 . 6 1 5 4 3 7 6 0 4 8 550 .3 6 0 . 3 2 7 1 5 1 3 9 6 3 8 4 539 .7 55 .3 2 9 4 6 2 6 2 6 105 .0 6.8 
CM
 3 4 9 5 3 0 1 6 4 7 0 3 2 1 6 4 7 1 . 2 5 1 . 5 3 5 1 6 7 5 3 7 0 8 8 4 7 9 . 3 4 8 . 8 3 3 4 7 5 4 8 0 I 95 .8 6.1 
CO
 
252114 .1 1 5 5 2 7 4 5 6 0 615 .9 6 7 . 6 1 0 1 5 1 9 2 7 1 2 0 6 0 2 . 6 62 .0 2 8 4 8 5 2 1 8 | 113 .0 7.4 
4 6 4 8 0 3 . 8 ND ND ND ND i ND | ND ND ND ND 
5 4 5 0 3 9 . 4 ND ND ND ND ND ND ND | ND I ND 
CD
 3 4 5 5 8 9 . 6 1907965601 552.1 60 .521 1 9 3 6 9 1 3 4 4 i 560 .5 j 57 .5 3 4 8 0 8 8 3 6 I 100.7 6 .5 
7 2 5 9 5 4 6 . 7 1 5 5 6 9 4 0 0 0 599 .9 I 6 5 . 8 3 0 1 6 0 2 1 8 7 3 6 ! 6 1 7 . 3 j 63 .5 3 0 3 1 7 8 0 6 j 116 .8 7.7 CO
 ND ND | ND j ND ND ND ND ND ND ND 
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9 44603 .1 ND ND ND - ND ND ND ND ND ND 
10 3 0 3 0 5 4 . 5 1 5 2 4 0 0 2 4 0 502 .9 5 5 . 0 5 3 1 6 5 6 6 2 4 3 2 546 .6 56.0 3 3 4 0 4 4 3 8 110 .2 7.2 
11 3 3 8 8 8 2 1 9 9 8 1 6 3 6 8 589 .6 6 4 . 6 9 2 2 0 1 4 5 8 0 9 6 594 .5 61.1 4 3 7 5 5 1 1 6 129.1 8.7 
12 3 3 0 3 2 7 2 0 2 4 9 4 2 0 8 613 .0 6 7 . 2 9 0 1 9 8 3 8 0 8 6 4 600 .6 61 .7 4 2 9 0 5 0 8 8 129.9 8.8 
13 3 0 7 6 2 3 . 6 ND ND ND ND ND ND ND ND ND 
14 ND ND ND ND ND ND ND ND ND ND 
15 3 4 8 7 4 2 . 2 1 9 5 6 5 7 4 5 6 5 6 1 . 0 6 1 . 5 1 5 1 9 7 6 9 8 7 6 8 566 .9 58 .2 4 0 4 2 5 4 2 8 115.9 7.7 
16 2 7 0 6 8 8 . 5 1 8 0 2 4 0 0 9 6 6 6 5 . 9 73 .161 1 8 1 3 2 2 2 8 8 6 6 9 . 9 69.1 3 9 6 5 0 5 4 0 146.5 10.0 
17 1 3 0 5 2 6 ND ND ND ND ND ND ND ND ND 
18 ND ND ND ND ND ND ND ND ND ND 
19 2 4 8 6 0 6 1 6 8 6 8 0 5 7 6 6 7 8 . 5 7 4 . 5 6 7 1 7 1 7 2 3 5 2 0 6 9 0 . 7 71 .3 3 2 9 3 6 5 9 4 132 .5 9.0 
20 2 3 4 9 3 5 . 7 1 3 3 0 7 2 8 5 6 5 6 6 . 4 6 2 . 1 1 3 1 3 6 2 8 7 8 2 4 580.1 59.6 2 7 1 1 5 5 0 8 115 .4 7.6 
21 ND ND ND ND ND ND ND ND ND ND 
22 2 7 2 8 4 . 6 ND ND ND ND ND ND ND ND ND 
23 2 5 6 8 5 9 . 8 1 4 0 4 2 5 3 9 2 546 .7 59 .922 1 3 8 4 8 1 9 6 8 539.1 55 .2 2 8 2 9 7 9 7 4 110 .2 7 .2 
24 288948 .1 1 4 7 3 1 9 7 4 4 509 .8 55 .828 1 5 8 3 1 9 8 4 0 547 .9 56.1 3 3 6 6 7 0 1 2 116 .5 7.7 
25 ND ND ND ND , ND ND ND ND ND ND 
26 ND ND ND ND ND ND ND ND ND ND 
27 2 8 9 1 7 4 1 3 0 4 9 9 8 2 4 4 5 1 . 3 49 .321 . 1 4 5 8 6 6 4 4 8 5 0 4 . 4 51 .5 5 4 5 5 2 8 4 4 188.7 13 .3 
28 2 8 1 7 9 0 . 5 1 3 4 0 7 5 7 3 6 4 7 5 . 8 5 2 . 0 4 4 1 4 9 9 0 7 7 9 2 532 .0 54 .4 5 5 2 3 4 9 6 0 196.0 13.9 
29 2 6 6 3 2 4 . 3 1 3 4 0 1 2 1 9 2 503 .2 55 .088 1 4 1 6 8 5 4 4 0 531 .8 54 .3 5 1 6 4 9 6 4 4 193 .9 13 .7 
30 1 3 6 5 2 0 . 7 ND ND ND ND ND ND ND ND ND 
31 5 0 5 4 0 ND ND ND ND ND ND ND ND ND 
32 2 6 4 4 0 4 . 4 1 3 6 2 5 0 4 0 0 515 .3 5 6 . 4 3 4 1 4 2 5 7 3 0 2 4 539 .2 55 .2 5 3 4 0 8 6 2 8 202 .0 14 .3 
33 2 5 8 4 7 6 1 3 6 1 5 3 3 7 6 526 .8 57 .706 1 3 9 3 2 4 3 5 2 539 .0 55 .2 5 0 3 5 5 0 2 0 194.8 13.8 
34 7 4 6 3 7 ND ND ND ND ND ND 7 0 1 3 4 8 2 94 .0 6.0 
35 ND ND ND ND ND ND ND ND ND ND 
ND = not detectable. 
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Recovery calculation 
Sample # Concentrated factor (CF) 
Lomefloxacin (ug/L) 
corrected by CF 
Recovery 
% -
Concentration corrected by recovery 
Ciprofloxacin (ug/L) Levofloxacin (yg/L) 
1 1000 6.8 68.3 88.3 80.9 
2 1000 6.1 61.1 84.3 79.9 
3 1000 7.4 74.4 90.8 83.2 
4 1000 ND ND ND ND 
5 1000 ND ND ND ND 
6 1000 6.5 65.0 93.2 88.5 
7 1000 7.7 77.4 85.1 82.1 
8 1000 ND ND ND ND 
CO
 
1000 ND ND ND ND 
10 1000 7.2 72.3 76.1 77.5 
11 1000 8.7 86.9 74.4 70.3 
12 1000 8.8 87.5 76.9 70.5 
13 972 ND ND ND | ND 
14 994 ND ND ND | ND 
15 1000 7.7 76.7 80.2 75.8 
16 1000 10.0 100.4 72.9 | 68.9 
17 1000 ND • ND ND ND 
18 1000 ND ND ND | ND 
19 1000 9.0 : 89.5 83.3 79.7 
20 1000 7.6 76.3 81.4 78.0 
21 1000 ND ND ND ND 
22 1000 ND ND ND ND 
23 1000 7.2 72.3 82.9 76.4 
24 1000 7.7 77.2 72.3 72.8 
25 1000 ND ND ND j ND 
26 1000 ND ND ND | ND 
27 1000 13 .3 6 6 . 5 74 .2 | 7 7 . 5 
28 1000 13.9 6 9 . 3 75.1 | 78 .5 
29 1000 13 .7 - - ' 68 .5 80 .4 79 .4 
30 1000 ND ND ND I ND 
31 1000 ND ND ND ND 
32 1000 14 .3 7 1 . 7 78 .8 i 77.1 
33 1000 13.8 6 8 ; 9 83 .8 80.1 
34 1000 6.0 29 .9 ND ND 
35 1000 ND ND ND ND 
Summary : 
5. Solid phase extraction recoveries ranged from 69-93% with reasonably good consistency. 
6. Amended lomefloxacin were not detected in the final samples. The disappearance of spiked lomefloxacin is likely caused by 
oxidation by residual oxidants due to incompletely quenching of the reaction samples. 
7. Ciprofloxacin and levofloxacin were not detected in the final samples. Degradation of ciprofloxacin and levofloxacin by residual 
oxidants over time may also contribute to the disappearance of ciprofloxacin and levofloxacin in the reaction samples. 
A p p e n d i x : 
C a l i b r a t i o n c u r v e : 
Standards of fluoroquinolones 
Peak Area 
Norfloxacin Ciprofloxacin Levofloxacin Lomefloxacin 
mg/L MW320 4 4 7 4 8 0 6 7 6 7 8 5 8 7 7 9 3 9 2 5 2 
S1 0.5 5 6 2 4 8 9 . 8 1 3 2 2 8 2 0 3 2 2 9 9 1 2 3 6 2 3 3 3 6 0 9 2 
S 2 
CM
 4 9 0 6 5 6 . 6 3 1 0 7 6 9 6 6 4 1 0 1 0 4 3 6 4 7 2 6 0 7 6 8 
S 3 5 553490 .1 5 3 2 6 7 3 8 4 6 4 3 5 3 4 6 4 8 5 8 6 1 2 7 2 
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S4 10 543672.1 76145216 82944264 107901472 
S5 15 542367.9 171717120 232969536 246389712 
Norfloxacin were added in all of the samples and standards as an internal standard. The peak area of each FQ (except for norfloxacin) 
was normalized by the peak area of 1 mg/L norfloxacin (i.e., Area/Area^)- Calibration curves were generated by plotting Area/Area^d 
ratios versus the concentration of each FQ. 
Area/ Areaistd 
Ciprofloxacin Levofloxacin Lemofloxacin 
mg/L MW332 MW362 MW352 
S1 0.5 8.0 13.7 14.1 
S2 2 27.0 46.9 47.6 
S3 5 56.1 74.1 85.4 
S4 10 98.0 118.4 157.9 











y = 8.972x +7.5688 
R 2 = 0.9969 
5 10 15 











y = 9.1628x + 21.622 
FT^ 0.9745 
Levofloxacin cone. (mg/L) 
S 150 
y = 1 Z 7 0 6 x + 1 8 . 1 9 7 
R 2 = 0.9832 
5 10 15 
Lerrofloxarinconc. (mg/L) 
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D. Analytical Results of 09/26/2006: 
Sample descriptions 
Sample # Date pH Precipitation 
T2 9/12/2006 2.91 No . • 
T3 9/12/2006 3.13 Yes 
T4 9/12/2006 2.96 .. No 
T5 9/12/2006 3.01 Yes 
T6 9/12/2006 2.78 No • 
T7 9/12/2006 2.88 Yes 
T8 9/12/2006 3.17 No 
T9 9/13/2006 2.74 Yes 
T10 9/13/2006 2.74 No ' ' 
T11 9/13/2006 3.24 Yes 
T12 9/13/2006 2.82 No , 
T13 9/13/2006 3.46 Yes 
T14 9/13/2006 2.77 No 
T15 9/13/2006 3.77 Yes 
T16 9/13/2006 2.83 No 
T17 9/13/2006 3.14 Yes 
T18 9/14/2006 2.74 No 
T19 9/14/2006 3.38 Yes 
T20 9/14/2006 3.01 No 
T21 9/14/2006 3.72 Yes 
T22 9/14/2006 3.10 No 
T23 9/14/2006 3.65 Yes 
T24 9/14/2006 3.18 No 
T25 9/14/2006 3.86 Yes 
T26 9/19/2006 2.84 No 
T27 9/19/2006 3.73 • No 
T28 9/19/2006 2.88 No 
T29 9/19/2006 3.60 Yes 
T31 9/19/2006 3.81 Yes 
T32 9/19/2006 2.09 No 
T33 9/19/2006 3.31 Yes 
Samples with precipitation were filtered by 0.7 \xm glass filter before solid phase extraction (SPE). All samples (544-1000 mL) were 
extracted through a 500 mg anion-exchange cartridge stacked on top of a 500 mg hydrophilic-lipophilic balance cartridge. Sample 
were amended with 15 |ig/L lomefloxacin prior to extraction for evaluation of extraction recoveries. After the extraction, 10 mg/L 
norfloxacin was spiked into the concentrated samples as an internal standard to account for signal suppression effects in different 
water matrices. 
R e s u l t s : 
Norfloxacin Ciprofloxacin Levofloxacin Lomefloxacin 
Sample # Areaistd Area Area/ Areaistd Conc.(mg/L). Area ; Area/ Areais t d Conc.(mg/L) Area Area/ Area^d Conc.(mg/L) 
T2 8368320 29156016 3.5 36.13 41560628 5.0 34.35 15413229 1.8 11.88 
T3 7277189 2514360 0.3 3.27 17793974 2.4 16.04 6448455 0.9 4.69 
? T4 8962956 32045050 3.6 37.08 46362536 5.2 35.84 18158254 2.0 13.26 
' T5 6703785 2625263 0.4 3.75 21705792 3.2 21.79 7599330 1.1 6.55 
T6 8372629 31715830 3.8 39.31 52404780 6.3 43.73 17092532 2.0 13.38 
T7 7202985 ND ND ND ND ND ND ND ND ND 
T8 9080636 30224354 3.3 34.50 47331172 5.2 36.13 17671046 1.9 12.66 
T9 7601765 ND ND ND 5275494 0.7 3.32 14811278 1.9 12.68 
T10 6405200 21328858 3.3 34.52 32896362 5.1 35.58 12849258 2.0 13.11 
T11 5062917 ND ND ND ND ND ND ND ND ND 
T12 8690580 22471694 2.6 26.72 36650872 4.2 28.91 14819736 1.7 10.85 
T13 4516581 ND ND ND 5261409 1.2 6.74 2435620 0.5 2.08 
17 
T14 8383128 18637732 2.2 I 22.93 333191161 4.0 I 27.14 13739848 } 1.6 ! 10.35 
T15 7352716 2078785 0.3 I 2.61 ND ND ND 9550360 I 1.3 7.79 
T16 7677074 19803384! 2.6 | 26.66 36713988) 4.8 I 33.01 14945212 | 1.9 I 12.67 
T17 6544585 ND ND ND ND ND ND ND ND ND 
T18 7763831 30586330 3.9 | 40.90 444081201 5.7 I 39.82 15583503 i 2.0 I 13.12 
J 1 9 5116759 2877766 0.6 I 5.54 216300681 4.2 I 28.98 7648693 I 1.5 ! 9.27 
T20 7635052 27200830 3.6 ! 36.95 420183841 5.5 ) 38.25 16064508 I 2.1 I 13.85 
T21 5665418 12720359 2.2 j 23.16 30149920! 5.3 i 36.93 11346432 ! 2.0 | 13.09 
T22 9275749 29482910 3.2 ! 32.93 474882481 5.1 I 35.46 16979312 | 1.8 [ 11.79 
T23 5429067 8765511 1.6 I 16.55 29072142) 5.4 j 37.17 10306907 I 1.9 { 12.30 
I T24 7493763 26774134 3.6 j 37.06 42782920! 5.7 I 39.74 15646282 j 2.1 j 13.73 
T25 6820361 9129087 1.3 i 13.66 31197760! 4.6 ) 31.50 11210018 j 1.6 I 10.39 
T26 9820726 19131766 1.9 I 20.05 27697388! 2.8 ( 18.76 16932466 J 1.7 | 10.99 
T27 6076800 8913758 1.5 I 15.01 274316901 4.5 i 31.06 10369371 j 1.7 j 10.86 
T.2.8 7254657 21901992 3.0 I 31.26 32876942! 4.5 I 31.19 12615877 i 1.7 ! 11.10 
T29 5819139 11778487 2.0 j 20.84 27747386) 4.8 i 32.91 10351645 S 1.8 } 11.40 
T31 5178971 14630146 2.8 I 29.23 30410218! 5.9 | 40.92 10354684 j 2.0 ! 13.06 
T32 6893653 23071740 3.3 I 34.69 35654020! 5.2 ! 35.84 12997677 j 1.9 » 12.21 
T33 4970432 2003595 0.4 : J 3.87 2094426 | 0.4 1.34 7246906 I 1.5 j 8.99 
ND = not detectable. 
Recovery calculation 





Concentration corrected by recovery 
Ciprofloxacin (ug/L) Levofloxacin (ug/L) 
T2 1000 11.9 79.2 45.6 43.4 
T3 1000 4.7 31.2 10.5 51.3 
T4 1000 13.3 88:4 41.9 | 40.5 
T5 1000 6.5 43.7 8.6 49.9 
T6 1000 13.4 89.2 44.1 49.0 
T7 1000 ND ND ND ND 
T8 1000 12.7 84.4 40.9 42.8 
18 
T9 1000 12 .7 84 .5 ND 3.9 
T 1 0 1000 13.1 87 .4 39.5 4 0 . 7 
T11 1000 ND - •-. ND ND ND 
T 1 2 1000 10.8 7 2 . 3 36 .9 4 0 . 0 
T 1 3 1000 2.1 13 .8 ND 4 8 . 7 
T 1 4 1000 10 .4 6 9 . 0 33 .2 39 .3 
T15 1000 7.8 51 .9 5.0 ! ND 
T16 1000 12 .7 84 .4 31 .6 39.1 
T 1 7 1 0 0 0 N D N D ND ND 
f i f r T18 1 0 0 0 13.1 87 .5 4 6 . 8 ! 45 .5 
T19 1 0 0 0 9 .3 6 1 . 8 9.0 | 46 .9 
T 2 0 1 0 0 0 13.8 . 9 2 . 3 4 0 . 0 41 .4 
T21 1 0 0 0 13.1 ; . 87 .3 26 .5 4 2 . 3 
T 2 2 1 0 0 0 11.8 78 .6 4 1 . 9 | 45.1 
T 2 3 1 0 0 0 12 .3 . 82 .0 2 0 . 2 4 5 . 3 
T 2 4 1 0 0 0 13 .7 91 .5 4 0 . 5 43 .4 
T25 1 0 0 0 10 .4 6 9 . 2 ••• 19.7 45 .5 
T26 5 4 4 2 0 . 2 • - ' • 7 3 . 3 2 7 . 4 25 .6 
T 2 7 1000 10 .9 72 .4 2 0 . 7 42 .9 
T28 1000 11.1 . 7 4 . 0 4 2 . 2 42.1 
T29 1 0 0 0 11 .4 7 6 . 0 - 2 7 . 4 4 3 . 3 
T31 1000 13.1 - 87.1 33 .6 4 7 . 0 
T 3 2 1000 12 .2 81 .4 42 .6 4 4 . 0 
T 3 3 1000 9 .0 59 .9 6.5 2 .2 
-Amended lomefloxacin were not detected in T7, T l 1 and T17 samples, and T3, T5 and T13 have low recovery. 
P r o d u c t ident i f i ca t ion 
From the preliminary results, the remaining ciprofloxacin concentration in the T3 sample is low compared to the T2 sample. Thus, T2 
and T3 can be an appropriate pair for product identification. Figure 1 shows the LC/MS SIM chromatograms of the T2 sample, T3 
sample, and a sample of ciprofloxacin oxidation product generated from reaction with HOC1. A product peak was identified by 
comparing the T2 and T3 chromatograms (Figure 1 (a) and 1(b)). The retention time of this product peak matches well with that of the 
ciprofloxacin oxidation product by HOC1 (Figure 1 (c)). Figure 2 shows the MS spectrum of the ciprofloxacin oxidation product, 
indicating that it is a m/z 263 compound resulted from dealkylation of the piperazine ring (Figure 3). The match in retention time and 
m/z ratio confirmed that the product in the T3 sample is a ciprofloxacin analog after full dealkylation of the piperazine ring (Product 1, 
M.W. = 262, shown in Figure 3). It is hypothesized that reaction of ciprofloxacin with ozone results first in partial dealkylation of the 
ciprofloxacin's piperazine ring, followed by complete dealkylation of the piperazine ring to yield the final Product 1 (Figure 3). 
Remaining levofloxacin concentrations in all of the samples Were relatively high (when compared to the remaining ciprofloxacin 
concentrations). These results indicate that levofloxacin is more difficult to degrade than ciprofloxacin. Due to limited degradation 
of the parent levofloxacin, there were not enough products formed and thus no detectable products could be identified by LC/MS. 
However, based on the similar structures of ciprofloxacin and levofloxacin, a similar degradation pathway may occur for levofloxacin. 









Figure 1 HPLC/MSD chromatograms (SIM: m/z = 263). (a) T2 sample, (b) T3 sample, (c) Oxidation product of ciprofloxacin by 
HOC1. 
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Figure 2 MS spectrum of ciprofloxacin oxidation product. 
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0 0
 0 0 
ciprofloxacin 
m/z=332 
Figure 3 Proposed oxidation products of ciprofloxacin. 
levofloxacin 
m/z=362 
Figure 4 Predicted oxidation products of levofloxacin. 
m/z=263 
Product 1 
A p p e n d i x : 
C a l i b r a t i o n c u r v e : 
Standards of fluoroquinolones 
Peak Area 
Norfloxacin Ciprofloxacin Levofloxacin Lomefloxacin 
mg/L MW320 MW332 MW362 MW352 
S1 1 18647460 1649085 3443171 3439607 
S2 5 16914994 9211777 16782620 15493539 
S3 10 16655911 17064226 29281522 28605386 
S4 25 17428140 41509176 64526240 66631236 
S5 50 17200340 82841104 121776672 116458848 
Norfloxacin were added in all of the samples and standards as an internal standard. The peak area of each FQ (except for norfloxacin) 
Was normalized by the peak area of 10 mg/L norfloxacin (i.e., Area/Area|S t d). Calibration curves were generated by plotting Area/Areaistd 
ratios versus the concentration of each FQ. 
Area/ Area|S t d 
Ciprofloxacin Levofloxacin Lemofloxacin 
mg/L MW332 MW362 MW352 
S1 1 0.09 0.18 0.18 
S2 5 0.54 0.99 0.92 
S3 10 1.02 1.76 1.72 
S4 25 2.38 3.70 3.82 
S5 50 4.82 7.08 6.77 
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Lemofloxacin cone. (mg/L) 
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E. Analytical Results of 10/04/06: 
Sample descriptions 
Sample # Date pH Precipitation 
T34 09/27/06 2.48 No 
T35 09/27/06 3.35 Yes 
T36 09/27/06 3.20 No 
T37 09/27/06 3.33 Yes 
T38 09/27/06 2.81 No 
T39 09/27/06 3.24 Yes 
T40 09/27/06 3.21 No ' 
T41 09/27/06 3.09 Yes 
Samples with precipitation were filtered by 0.7 um glass fiber filters before solid phase extraction (SPE). Each sample was extracted 
through a 500 mg anion-exchange cartridge stacked on top of a 500 mg hydrophilic-lipophilic balance cartridge. Samples were 
amended with 15 ug/L lomefloxacin prior to extraction for evaluation of extraction recoveries. After the extraction, 10 mg/L 
norfloxacin was spiked into the concentrated samples as an internal standard to account for signal suppression effects in different 
water matrices. 
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R e s u l t s : 
Norfloxacin Ciprofloxacin Levofloxacin Lomefloxacin 
Sample # Areaistd Area Area/ Area^d Conc.(mg/L) Area Area/Area^td I Conc.(mg/L) Area Area/ Areais t d Conc.(mg/L) 
T34 8242603 264125841 3.2 33.20 39069016 4.7 32.70 14461174 1.8 11.22 
T35 6276073 ND | ND | ND 11089077| 1.8 | 11.11 3882611 | 0.6 I 2.67 
T36 9726196 28723612) 3.0 30.57 42669028! 4.4 30.14 16356123 1.7 10.67 
T37 7258963 ND ND ND ND ND ND ND ND ND 
T38 8959744 28156886 3.1 32.55 43216320 4.8 33.31 16217826 1.8 11.64 
T39 6944254 ND ND ND ND ND ND ND ND ND 
X40 9426068 33391374 3.5 36.74 49353308) 5.2 I 36.30 18345684 1.9 12.66 
T41 6531281 ND | ND | ND ND | ND | ND ND J ND | ND 
ND = not detectable. 
Recovery calculation 





Concentration corrected by recovery 
Ciprofloxacin (ng/L) j Levofloxacin (ug/L) 
T34 1000 11.2 74.8 44.4 43.7 
T35 1000 2.7 17.8 ND 62.3 
T36 1000 10.7 71.1 43.0 I 42.4 
T37 1000 ND ND ND ND 
T38 1000 11.6 77.6 42.0 42.9 
T39 1000 ND ND ND j ND 
T40 1000 12.7 84.4 43.5 43.0 
T41 1000 ND ND ND ND 
-Amended lome: loxacin were not detected in the T37, T39 and T41 samples anc the T35 sample has lower recovery. 
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A p p e n d i x : 
C a l i b r a t i o n c u r v e : 
Standards of fluoroquinolones 
Peak Area 
Norfloxacin Ciprofloxacin Levofloxacin Lomefloxacin 
mg/L MW320 MW332 MW362 MW352 i 
S1 1 18460985 1632594 3408739 3405211 ' 
S2 5 16745844 9119659 16614794 15338604: 
S3 10 ; 16489352 16893584 28988707 28319332. 
S4 25 17253859 41094084 63880978 65964924 
S5 50 ~ 17028337 82012693 120558905 115294260 
Norfloxacin were added in all of the samples and standards as an internal standard. The peak area of each FQ (except for norfloxacin) 
was normalized by the peak area of 10 mg/L norfloxacin (i.e., Area/Area^d). Calibration curves were generated by plotting Area/Area^d 
ratios versus the concentration of each FQ. 
Area/ Areai s t d 
Ciprofloxacin Levofloxacin Lemofloxacin 
mg/L MW332 MW362 MW352 
S1 1 0.09 0.18 0.18 
S2 5 0.54 0.98 0.91 
S3 10 1.01 1.74 1.70 
S4 25 2.36 3.67 3.78 
S5 50 4.77 7.01 6.70 
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